RxSight, Inc. (RXST) has a negative trailing P/E of -7.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -13.85%.
Criteria proven by this page:
Overall SharesGrow Score: 52/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | 2.4 | 0.00 | -1.00 | 136.18 | - |
| 2020 | 11.1 | -0.14 | -1.03 | 20.79 | - |
| 2021 | -6.3 | 0.01 | 2.23 | 13.63 | - |
| 2022 | -5.3 | -0.15 | 3.90 | 7.15 | - |
| 2023 | -28.6 | 0.69 | 8.66 | 15.60 | - |
| 2024 | -48.7 | 0.98 | 4.75 | 9.55 | - |
| 2025 | -11.0 | -0.33 | 1.56 | 3.19 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $0.95 | $2.24M | $126.22M | 5632.3% |
| 2020 | $0.12 | $14.68M | $27.58M | 187.9% |
| 2021 | $-1.78 | $22.59M | $-48.69M | -215.5% |
| 2022 | $-2.41 | $49.01M | $-66.76M | -136.2% |
| 2023 | $-1.41 | $89.08M | $-48.61M | -54.6% |
| 2024 | $-0.71 | $139.93M | $-27.46M | -19.6% |
| 2025 | $-0.95 | $134.48M | $-38.94M | -29% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.30 | $-1.39 – $-1.21 | $130.97M | $129.83M – $132.07M | 4 |
| 2027 | $-1.18 | $-1.55 – $-0.81 | $143.87M | $140.19M – $148.34M | 5 |
| 2028 | $-1.18 | $-1.18 – $-1.18 | $149M | $148.97M – $149.03M | 2 |
